CA2946761C - Methods of treating incontinence and other sphincter deficiency disorders - Google Patents

Methods of treating incontinence and other sphincter deficiency disorders Download PDF

Info

Publication number
CA2946761C
CA2946761C CA2946761A CA2946761A CA2946761C CA 2946761 C CA2946761 C CA 2946761C CA 2946761 A CA2946761 A CA 2946761A CA 2946761 A CA2946761 A CA 2946761A CA 2946761 C CA2946761 C CA 2946761C
Authority
CA
Canada
Prior art keywords
sphincter
sdf
incontinence
gastrointestinal
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2946761A
Other languages
English (en)
French (fr)
Other versions
CA2946761A1 (en
Inventor
James K. WILLIAMS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wake Forest University Health Sciences
Original Assignee
Wake Forest University Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wake Forest University Health Sciences filed Critical Wake Forest University Health Sciences
Publication of CA2946761A1 publication Critical patent/CA2946761A1/en
Application granted granted Critical
Publication of CA2946761C publication Critical patent/CA2946761C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2946761A 2014-05-08 2015-04-30 Methods of treating incontinence and other sphincter deficiency disorders Active CA2946761C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461990190P 2014-05-08 2014-05-08
US61/990,190 2014-05-08
PCT/US2015/028490 WO2015171417A1 (en) 2014-05-08 2015-04-30 Methods of treating incontinence and other sphincter deficiency disorders

Publications (2)

Publication Number Publication Date
CA2946761A1 CA2946761A1 (en) 2015-11-12
CA2946761C true CA2946761C (en) 2023-08-22

Family

ID=54392862

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2946761A Active CA2946761C (en) 2014-05-08 2015-04-30 Methods of treating incontinence and other sphincter deficiency disorders

Country Status (6)

Country Link
US (2) US10420818B2 (https=)
EP (1) EP3139945B1 (https=)
JP (1) JP2017514875A (https=)
AU (1) AU2015256383B2 (https=)
CA (1) CA2946761C (https=)
WO (1) WO2015171417A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015256383B2 (en) 2014-05-08 2020-05-21 Wake Forest University Health Sciences Methods of treating incontinence and other sphincter deficiency disorders
AU2018244776B2 (en) 2017-03-30 2023-12-14 Wake Forest University Health Sciences Methods of treatment for kidney disease
WO2019032930A1 (en) * 2017-08-11 2019-02-14 Wake Forest University Health Sciences USE OF CXCL12 FOR THERAPY AFTER SURGERY OF THE PROSTATE
CN114159471A (zh) * 2020-09-11 2022-03-11 永立荣生医股份有限公司 包括羊水干细胞球的医药组合物及其治疗尿失禁的用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US311219A (en) 1885-01-27 Mechanical toy
JP2609851B2 (ja) * 1986-09-04 1997-05-14 悦子 柿崎 徐放性注射剤
US5385561A (en) 1994-01-18 1995-01-31 Bard International, Inc. Apparatus and method for injecting a viscous material into the tissue of a patient
DE4414755C2 (de) * 1994-04-27 2000-11-16 Lohmann Therapie Syst Lts Kollagenzubereitung zur gesteuerten Abgabe von Wirkstoffen, Verfahren und Verwendung
US5588960A (en) 1994-12-01 1996-12-31 Vidamed, Inc. Transurethral needle delivery device with cystoscope and method for treatment of urinary incontinence
US5925629A (en) 1997-10-28 1999-07-20 Vivus, Incorporated Transurethral administration of androgenic agents for the treatment of erectile dysfunction
CA2412436C (en) 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
WO2003005889A2 (en) 2001-07-10 2003-01-23 Ams Research Corporation Surgical kit for treating prostate tissue
KR20070085288A (ko) * 2004-09-24 2007-08-27 안지오블라스트 시스템스 인코퍼레이티드 간엽 전구세포의 증식 및/또는 생존성 증강 방법
WO2007035843A2 (en) 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
CA2640087A1 (en) 2006-01-25 2007-08-02 Mount Sinai School Of Medicine Methods and compositions for modulating the mobilization of stem cells
US7598028B2 (en) 2006-11-28 2009-10-06 The Regents Of The University Of Michigan Compositions and methods for detecting and treating prostate disorders
US20080311219A1 (en) * 2007-06-15 2008-12-18 Anna Gosiewska Tissue Fragment Compositions for the Treatment of Incontinence
ATE543507T1 (de) 2007-11-07 2012-02-15 Ono Pharmaceutical Co Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung
WO2009079451A2 (en) * 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
EA201170297A1 (ru) 2008-08-09 2011-08-30 Массачусетс Инститьют Оф Текнолоджи Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей
CA2772610C (en) 2009-08-28 2018-01-23 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
US9308277B2 (en) * 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
AU2015256383B2 (en) 2014-05-08 2020-05-21 Wake Forest University Health Sciences Methods of treating incontinence and other sphincter deficiency disorders

Also Published As

Publication number Publication date
EP3139945A4 (en) 2017-11-29
EP3139945A1 (en) 2017-03-15
CA2946761A1 (en) 2015-11-12
EP3139945B1 (en) 2025-08-27
US11160848B2 (en) 2021-11-02
NZ727292A (en) 2024-03-22
WO2015171417A1 (en) 2015-11-12
US20190365860A1 (en) 2019-12-05
US20170106050A1 (en) 2017-04-20
AU2015256383A1 (en) 2017-01-05
JP2017514875A (ja) 2017-06-08
AU2015256383B2 (en) 2020-05-21
US10420818B2 (en) 2019-09-24

Similar Documents

Publication Publication Date Title
US11160848B2 (en) Methods of treating gastrointestinal sphincter deficiency disorders
KR102559262B1 (ko) 심근증, 진구성 심근경색 및 만성심부전의 치료약
KR102146815B1 (ko) Hmgb1 단편을 이용한 신규 심근경색의 치료법
Naranjo et al. Regenerative medicine approaches for age-related muscle loss and sarcopenia: a mini-review
Heber–Katz et al. The scarless heart and the MRL mouse
US20170232276A1 (en) Treatment of fibrosis using deep tissue heating and stem cell therapy
CN1824289A (zh) P物质用于间充质干细胞的动员或增殖以及用于伤口愈合或促进伤口愈合的用途
JP2023011938A (ja) ファーバー病を治療するための組成物及び方法
JP2025069172A (ja) 腎臓疾患の治療方法
Tu et al. Somatic Braf V600E mutation in the cerebral endothelium induces brain arteriovenous malformations
Williams et al. Methods of treating incontinence and other sphincter deficiency disorders
KR102445482B1 (ko) 오가노이드 및 항염증제를 포함하는 염증성 장질환의 예방 또는 치료용 약학 조성물
US11654181B2 (en) Use of CXCL12 for therapy after prostate surgery
KR20140041263A (ko) 말초혈액 단핵세포를 유효성분으로 포함하는 예방 또는 치료용 약제학적 조성물
Stewart The physiology of stem cells: potential for the elderly patient
US12491211B2 (en) Therapy for interstitial cystitis by pluripotent stem cells
JP2007537160A (ja) 虚血／再灌流障害治療用のアドレノメデュリン及びアドレノメデュリン結合タンパク質
ES2903411T3 (es) AMD3100 para el tratamiento y/o la prevención de caquexia, y composición farmacéutica del mismo
KR20250162146A (ko) 라파마이신을 함유 약물 전달체가 접합된 줄기세포 및 이의 용도
CN121445740A (zh) Gsk2879552在制备治疗或缓解心脏病的药物中的应用
CN115531515A (zh) 肿瘤靶向药物及其应用
McTiernan et al. Experimental Heart Failure Models of Cytokine Overexpression
Zhang et al. e0192 A metaanalysis of right ventricular septum pacing

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200331

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250311

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250311

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250311

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260317

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260317